ZA201704743B - Mangiferin-6-o-berberine salt and preparation method and use thereof - Google Patents
Mangiferin-6-o-berberine salt and preparation method and use thereofInfo
- Publication number
- ZA201704743B ZA201704743B ZA2017/04743A ZA201704743A ZA201704743B ZA 201704743 B ZA201704743 B ZA 201704743B ZA 2017/04743 A ZA2017/04743 A ZA 2017/04743A ZA 201704743 A ZA201704743 A ZA 201704743A ZA 201704743 B ZA201704743 B ZA 201704743B
- Authority
- ZA
- South Africa
- Prior art keywords
- mangiferin
- preparation
- berberine salt
- berberine
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510005381 | 2015-01-07 | ||
PCT/CN2016/070229 WO2016110250A1 (en) | 2015-01-07 | 2016-01-06 | Mangiferin-6-o-berberine salt and preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201704743B true ZA201704743B (en) | 2018-12-19 |
Family
ID=56355531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2017/04743A ZA201704743B (en) | 2015-01-07 | 2017-07-13 | Mangiferin-6-o-berberine salt and preparation method and use thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US10285969B2 (en) |
EP (1) | EP3243823B1 (en) |
JP (1) | JP6460498B2 (en) |
KR (1) | KR101986983B1 (en) |
CN (1) | CN107108603B (en) |
AU (1) | AU2016206179B2 (en) |
BR (1) | BR112017014416A2 (en) |
CA (1) | CA2970561C (en) |
RU (1) | RU2670088C1 (en) |
WO (1) | WO2016110250A1 (en) |
ZA (1) | ZA201704743B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018006737A1 (en) * | 2016-07-04 | 2018-01-11 | 常州德泽医药科技有限公司 | Mangiferin-6-o-calcium salt and preparation method and use thereof |
JP2019178070A (en) * | 2018-03-30 | 2019-10-17 | 大正製薬株式会社 | Mitol production promoter |
CN108570046B (en) * | 2018-05-31 | 2019-10-11 | 闽江学院 | A kind of berberine-Chrysin pharmaceutical co-crystals and preparation method thereof |
JP7185226B2 (en) * | 2018-11-22 | 2022-12-07 | 国立大学法人 鹿児島大学 | AMPK Activator Containing 1,5-Anhydrofructose Derivative |
CN115414350B (en) * | 2022-09-22 | 2023-08-04 | 湖北省农业科学院畜牧兽医研究所 | Application of mangiferin in preparing medicine for inhibiting haemophilus parasuis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000042507A (en) * | 1998-12-21 | 2000-07-15 | 박원배 | 5.,6-dihydrodibenzo(a,g)quinolizinium derivative having inhibition effect on bio-synthesis of cholesterol |
CN101066275A (en) * | 2007-06-12 | 2007-11-07 | 广西中医学院 | Mangiferin-berberine composition |
CN101921270A (en) * | 2009-06-16 | 2010-12-22 | 海南德泽药物研究有限公司 | Mangiferin berberine salt, preparation method thereof and use thereof |
CN103816153A (en) * | 2013-12-10 | 2014-05-28 | 无锡万全医药技术有限公司 | Application of compound DZCY06 in preparation of drugs for treating diabetes |
-
2016
- 2016-01-06 EP EP16734910.9A patent/EP3243823B1/en active Active
- 2016-01-06 CN CN201680003926.3A patent/CN107108603B/en not_active Expired - Fee Related
- 2016-01-06 CA CA2970561A patent/CA2970561C/en not_active Expired - Fee Related
- 2016-01-06 JP JP2017536871A patent/JP6460498B2/en not_active Expired - Fee Related
- 2016-01-06 WO PCT/CN2016/070229 patent/WO2016110250A1/en active Application Filing
- 2016-01-06 KR KR1020177018073A patent/KR101986983B1/en active IP Right Grant
- 2016-01-06 RU RU2017123522A patent/RU2670088C1/en active
- 2016-01-06 BR BR112017014416A patent/BR112017014416A2/en not_active IP Right Cessation
- 2016-01-06 AU AU2016206179A patent/AU2016206179B2/en not_active Ceased
-
2017
- 2017-06-12 US US15/619,936 patent/US10285969B2/en not_active Expired - Fee Related
- 2017-07-13 ZA ZA2017/04743A patent/ZA201704743B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10285969B2 (en) | 2019-05-14 |
RU2670088C1 (en) | 2018-10-18 |
US20170273940A1 (en) | 2017-09-28 |
JP6460498B2 (en) | 2019-01-30 |
WO2016110250A1 (en) | 2016-07-14 |
BR112017014416A2 (en) | 2018-03-20 |
EP3243823A4 (en) | 2018-07-18 |
AU2016206179B2 (en) | 2018-08-02 |
EP3243823B1 (en) | 2020-12-16 |
CN107108603A (en) | 2017-08-29 |
AU2016206179A1 (en) | 2017-07-06 |
EP3243823A1 (en) | 2017-11-15 |
CN107108603B (en) | 2019-06-07 |
KR20170092628A (en) | 2017-08-11 |
CA2970561C (en) | 2019-07-23 |
KR101986983B1 (en) | 2019-06-07 |
CA2970561A1 (en) | 2016-07-14 |
JP2018501293A (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
ZA201605154B (en) | Insecticidal proteins and methods for their use | |
ZA201702161B (en) | Insecticidal proteins and methods for their use | |
EP3338786C0 (en) | Shenlingbaizhu granules and preparation method thereof | |
HK1253049A1 (en) | Glycan-interacting compounds and methods of use | |
EP3159424A4 (en) | Rebar and preparation method thereof | |
EP3299369A4 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
GB201514756D0 (en) | Compound and method of use | |
GB201514760D0 (en) | Compounds and method of use | |
HK1215280A1 (en) | Saliva preserving solution and preparation method and use thereof | |
PL3398598T3 (en) | Sulfonamide derivative and preparation method and use thereof | |
ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
EP3235851A4 (en) | Nylon salt and preparation method therefor | |
GB201520255D0 (en) | Composition and method | |
HK1214767A1 (en) | Tablet-formed pharmaceutical composition and preparation method thereof | |
EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
PT3263133T (en) | Pyridinone compound and use thereof | |
IL254597A0 (en) | Crystalline form of ahu377, preparation method and use thereof | |
SI3349594T1 (en) | Salt substitute composition and use thereof | |
GB201509420D0 (en) | Composition and method | |
HRP20180716T1 (en) | New ivabradine salt and its preparation process | |
IL253174A0 (en) | Nanoparticles and methods for preparation thereof | |
GB201513492D0 (en) | Method and composition | |
EP3479829A4 (en) | Mangiferin-6-o-calcium salt and preparation method and use thereof | |
GB2545167B (en) | Cloches and use thereof |